Last reviewed · How we verify

NCT06832163

Close Loop Smart Weaning for INO With PPHN

Not yet recruiting NA Last updated 18 February 2025
What this trial tests

NA trial testing Nitric Oxide Generation and Delivery System in Persistent Pulmonary Hypertension of the Newborn in 30 participants. Not yet recruiting.

Timeline
1 March 2025
Primary endpoint
31 December 2026
31 December 2026

Quick facts

Lead sponsorChildren's Hospital of Fudan University
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsequential
Maskingnone
Primary purposetreatment
Enrollment30
Start date1 March 2025
Primary completion31 December 2026
Estimated completion31 December 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Children's Hospital of Fudan University

Who can join

Eligibility, any sex, with Persistent Pulmonary Hypertension of the Newborn or Inhaled Nitric Oxide. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In contemporary clinical practice concerning the administration of inhaled nitric oxide (iNO) within neonatal intensive care units (NICUs), a stepwise reduction approach is frequently employed in accordance with established neonatal guidelines. Nonetheless, the comparative advantages of a linear reduction strategy-characterized by a gradual decrease in inhalation concentration-over the traditional stepwise method in terms of efficacy and safety have yet to be conclusively established. Furthermore, existing iNO delivery devices necessitate that healthcare professionals manually adjust parameters at intervals dictated by the patient's condition. This reliance on subjective clinical judgment often results in variability and a lack of standardization in the duration of the weaning process. Additionally, the protracted and intricate nature of the weaning procedure considerably heightens the workload for healthcare staff. Importantly, the development of a scientifically grounded, standardized, and real-time feedback mechanism for weaning may enhance clinical outcomes for patients and mitigate the risks associated with inappropriate weaning practices or inconsistent manual interventions. Consequently, this study seeks to leverage the newly introduced "intelligent closed-loop weaning" feature of the latest generation of iNO devices to facilitate automated linear concentration reduction during the weaning process. This innovation aims to alleviate the burden on healthcare personnel while establishing a more standardized and scientifically robust weaning protocol. However, it is noteworthy that there is currently a lack of clinical evidence, both domestically and internationally, regarding the safety and efficacy of this device's weaning protocol, underscoring the urgent need to validate its safety and effectiveness in real-world clinical settings.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Nitric Oxide Generation and Delivery System

Trials testing the same drug.

Other recruiting trials for Persistent Pulmonary Hypertension of the Newborn

Currently open trials in the same condition.

Other Children's Hospital of Fudan University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06832163.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing